Foundation for the National Institutes and Partners Launch a Study of Minimal Residual Disease in Acute Lymphoblastic Leukemia
The Foundation for the National Institutes of Health (FNIH) and partners from the National Cancer Institute (NCI), a component of the National Institutes of Health, NCI-designated Cancer Centers, universities, hospitals, industry partners, advocacy groups and the Food and Drug Administration, are launching a three-year initiative to determine whether minimal residual disease (MRD) can be used to predict response to therapy in adult Acute Lymphoblastic Leukemia (ALL).
Donate and Support Today
Take Action to Support Life-Saving Medical Research
Every dollar counts! Your gift to the FNIH makes our efforts possible. With your help—and in partnership with NIH—the Foundation is advancing biomedical research and training.
Donate with Confidence
For 10 years, Charity Navigator has rated FNIH as an organization that exceeds industry standards.
News and Highlights
The 2013 annual report of the Foundation for the National Institutes of Health (FNIH), New Pathways to Discovery, is now online.
FNIH announces a Call for Nominations for the 2015 Lurie Prize in Biomedical Sciences, which awards $100,000 to an outstanding young biomedical investigator. Submit nominations online by October 14, 2014.
The FNIH is accepting applications for two funding opportunities in the Accelerating Medicines Partnership’s Type 2 Diabetes project. Responses to the first Request for Proposals (RFPs) are due by August 11, 2014. More >>
Solomon H. Snyder, M.D., Vice Chairman for Science of the FNIH Board of Directors and Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry from the Solomon H. Snyder Department of Neuroscience at Johns Hopkins University has been named a winner of the 2014 Warren Alpert Foundation Prize. More >>